• PCN24 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIAL (GREAT) IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER IN TAIWAN

    Nov 1, 2004, 00:00

  • PCV4 FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION

    Nov 1, 2004, 00:00

  • PNL20 A SIMPLIFIED SEVERITY SCALE FOR THE ASSESSMENT OF RESTLESS LEGS SYNDROME- THE DESYR STUDY GROUP

    Nov 1, 2004, 00:00

  • PHP31 SENSIBLE FLEXIBILITY OR UNNECESSARY DUPLICATION] THE USE OF DECISION MODELLING IN NICE APPRAISALS

    Nov 1, 2004, 00:00

  • PDB27 A MULTIDIMENSIONAL HEALTH CARE INTERVENTION ASSESSMENT- THE CO-ORDINATED DIABETES HEALTHCARE NETWORK

    Nov 1, 2004, 00:00

  • PNL21 INDEPENDENT EFFECT OF DYSKINESIA ON HEALTHRELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSONS DISEASE-A MULTIVARIATE ANALYSIS

    Nov 1, 2004, 00:00

  • PNL15 RETROSPECTIVE EVALUATION OF THE DOSE OF DYSPORT IN THE CLINICAL MANAGEMENT OF CERVICAL DYSTONIA OR BLEPHAROSPASM-THE REAL DOSE STUDY EXPANSION-COST CONSIDERATIONS BASED ON DRUG START

    Nov 1, 2004, 00:00

  • PPN10 QUANTIFICATION OF SUSPECTED ADDICTION TREATMENT OF NARCOTIC ANALGESICS USING PRESCRIPTION SEQUENCE ANALYSIS- EXPERIENCE OF A STATE-BASED WORKERS COMPENSATION SYSTEM

    Nov 1, 2004, 00:00

  • PAR28 ASSESSING INTANGIBLES IN BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS (RA). A WILLINGNESS TO PAY (WTP) STUDY IN SPANISH PATIENTS

    Nov 1, 2004, 00:00

  • PMH2 GEO OBSERVATIONAL STUDY- 12 MONTHS DISEASE CHARACTERISTICS, SIDE EFFECTS AND SOCIOECONOMIC STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY

    Nov 1, 2004, 00:00

  • PCN45 MODELING EFFECT IN PHARMACOECONOMICS ANALYSIS USING ARTIFICIAL NEURAL NETWORKS

    Nov 1, 2004, 00:00

  • CV8 PHARMACOECONOMIC CONSEQUENCES OF PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE CZECH REPUBLIC

    Nov 1, 2004, 00:00

  • MC1 COMPLIANCE, ADHERENCE, AND PERSISTENCE- A COMPARISON OF THREE METHODOLOGIES FOR EVALUATING PATIENT COMPLIANCE USING PRESCRIPTION CLAIMS DATA

    Nov 1, 2004, 00:00

  • UC3 A FIVE-LEVEL VERSION OF EQ-5D

    Nov 1, 2004, 00:00

  • PRS3 PHARMACOECONOMY AND ANTIBIOTIC TREATMENT WITHIN THE SLOVAK REPUBLIC

    Nov 1, 2004, 00:00

  • PAA3 RESOURCE USE IN PATIENTS WITH EXACERBATIONS OF ASTHMA WITH DIFFERENT UNDERLYING DEGREES OF SEVERITY IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2004, 00:00

  • PES19 SENSITIVE SKIN- QUALITY OF LIFE IMPACT

    Nov 1, 2004, 00:00

  • PCV67 USE OF CLOPIDOGREL AFTER ISCHEMIC VASCULAR EVENTS IN THE THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PNL13 PROFILE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME AND ESTIMATION OF THEIR ANNUAL COST IN AN AMBULATORY CARE SETTING, IN FRANCE

    Nov 1, 2004, 00:00

  • PNL5 SOCIAL COSTS OF PARKINSON DISEASE IN ITALY

    Nov 1, 2004, 00:00

  • PAA8 COST ESTIMATION IN CLINICAL PIGGY-BACK STUDIES WITH DISCONTINUATIONS-COMPARISON OF DIFFERENT APPROACHES

    Nov 1, 2004, 00:00

  • PES7 A PHARMACOECONOMIC ANALYSIS OF THE FIXED COMBINATION LATANOPROST/TIMOLOL VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF PATIENTS WITH GLAUCOMA IN SPAIN

    Nov 1, 2004, 00:00

  • PCV32 SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS 1442-A PROSPECTIVE 3-YEAR PHARMACOECONOMIC STUDY

    Nov 1, 2004, 00:00

  • EE4 COMPARING TREATMENT COSTS ASSOCIATED WITH SCREENING FOR GLAUCOMAVS NOT SCREENING- EVALUATING THE ECONOMIC IMPACT OF THE NEW HEDIS MEASURE

    Nov 1, 2004, 00:00

  • QL6 THE BARTHEL PREFERENCE INDEX (BPI)- A NEW CONDITION-SPECIFIC PREFERENCE INDEX (COPI) FOR USE IN STROKE

    Nov 1, 2004, 00:00

  • QL8 DEVELOPMENT AND VALIDATION OF THE DIAPASON- A TREATMENT SATISFACTION QUESTIONNAIRE FOR INDIVIDUALS WITH TYPE-2 DIABETES

    Nov 1, 2004, 00:00

  • PCNIO COST-EFFECTIVENESS-ANALYSIS OF BREAST CANCER DIAGNOSIS WITH CAD (COMPUTER AIDED DETECTION)

    Nov 1, 2004, 00:00

  • PPN3 AN OBSERVATIONAL STUDY OF INTRAVENOUS PATIENTCONTROLLED ANALGESIA RESOURCE UTILIZATION AT AN ACADEMIC MEDICAL CENTER

    Nov 1, 2004, 00:00

  • PCV70 DECISION ANALYSIS AND COSTS OF LOW MOLECULAR WEIGHT HEPARINS- A CASE STUDY IN FRANCE

    Nov 1, 2004, 00:00

  • PDB8 WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?

    Nov 1, 2004, 00:00

  • IN3 ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN GREECE

    Nov 1, 2004, 00:00

  • PMH27 THE EFFECT OF RAISING THREE TIER CO-PAYMENTS ON SSRI ANTIDEPRESSANT COMPLIANCE RATES

    Nov 1, 2004, 00:00

  • PNL7 COSTS OF STROKE UNIT CARE IN GERMANY

    Nov 1, 2004, 00:00

  • QL7 VALIDATION OF A PATIENT-ADMINISTERED QUESTIONNAIRE TO MEASURE THE SEVERITY OF LOWER URINARY TRACT SYMPTOMS IN UNCOMPLICATED URINARY TRACT INFECTION-THE UTI SYMPTOM ASSESSMENT (USA) QUESTIONNAIRE

    Nov 1, 2004, 00:00

  • PES23 SUN SENSITIVITY AND PERSONAL BEHAVIOURS

    Nov 1, 2004, 00:00

  • PCNI COST-EFFECTIVENESS OF APREPITANT GIVEN WITH STANDARD ANTIEMETICS IN PATIENTS RECEIVING CHEMOTHERAPY IN OFFICE-BASED SETTINGS IN GERMANY

    Nov 1, 2004, 00:00

  • PCVI4 AN ECONOMIC ANALYSIS OF CATHETER ABLATION FORTHE TREATMENT OF VENTRICULAR TACHYCARDIA

    Nov 1, 2004, 00:00

  • PHP7 THE IMPACT OF PHARMACEUTICAL MARKET COMPETITION ON PRICE AND REIMBURSEMENT STATUS OF PATENTED DRUGS IN THE NETHERLANDS, BELGIUM, FRANCE AND GERMANY

    Nov 1, 2004, 00:00

  • PMC22 REVIEW OF INSTRUMENTS MEASURING TREATMENT SATISFACTION WITH MEDICATION

    Nov 1, 2004, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2004, 00:00

  • PES12 NON-MEDICAL COSTS RELATED TO VISUAL IMPAIRMENT IN FOUR EUROPEAN COUNTRIES (FRANCE, GERMANY, ITALY AND THE UNITED KINGDOM)

    Nov 1, 2004, 00:00

  • PCV77 ASSESSING THE LIKELIHOOD OF FRACTURE WITH ORAL ANTI-SPASTICITY MEDICATIONS- A CASE-CONTROL STUDY

    Nov 1, 2004, 00:00

  • PAR 17 LINGUISTIC ADAPTATION AND VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS) INTO SPANISH

    Nov 1, 2004, 00:00

  • PAR 16 CO-PAYMENTS IN RHEUMATOID ARTHRITIS OBSERVED IN A GERMAN COHORT

    Nov 1, 2004, 00:00

  • Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders- A Markov Model

    Sep 1, 2004, 00:00

  • Publication of Pharmacoeconomic Data Submitted to Reimbursement or Clinical Guidelines Agencies

    Sep 1, 2004, 00:00

  • Medical Care Costs Associated with Postmenopausal Estrogen Plus Progestogen Therapy

    Sep 1, 2004, 00:00

  • Dermatological Applications of Needs-Based Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Technology, Regulations, and Value in Health

    Sep 1, 2004, 00:00

  • Requirements for Quality of Life Instruments in Clinical Research

    Sep 1, 2004, 00:00

  • Effectiveness of Needs-Based Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Estimating Survival for Cost-Effectiveness Analyses- A Case Study in Atherothrombosis

    Sep 1, 2004, 00:00

  • Adapting Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Defining Patient-Reported Outcomes

    Sep 1, 2004, 00:00

  • Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple Sclerosis

    Sep 1, 2004, 00:00

  • Integrating Patient-Reported Outcomes

    Sep 1, 2004, 00:00

  • Comparing Medications in a Therapeutic Area Using an NNT Model

    Sep 1, 2004, 00:00

  • Comparison of the HUI3 with the SF-36 Preference Based SF-6D in a Clinical Trial Setting

    Sep 1, 2004, 00:00

  • Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making- How Are Cost-Effectiveness Thresholds Expected to Emerge?

    Sep 1, 2004, 00:00

  • Development of Needs-Based Quality of Life Instruments

    Sep 1, 2004, 00:00

  • The Needs-Based Approach to Quality of Life Assessment

    Sep 1, 2004, 00:00

  • Portfolio Theory and Cost-Effectiveness Analysis- A Further Discussion

    Sep 1, 2004, 00:00

  • Summary of Needs-Based Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Use of Outcomes Research in Assuring Patient Safety and Quality Care, Second Plenary Session, ISPOR 8th Annual International Meeting, Arlington, VA, USA

    Sep 1, 2004, 00:00

  • Application of Rasch Analysis in the Development and Application of Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Systematic Assessment of Decision Models in Parkinson's Disease

    Sep 1, 2004, 00:00

  • Return on Investment of Different Combinations of Bupropion SR Dose and Behavioral Treatment for Smoking Cessation in a Health Care Setting- An Employer's Perspective

    Sep 1, 2004, 00:00

  • Cost-Effectiveness Analysis of Bicalutamide (Casodex™)* * Casodex™ is a registered trademark for AstraZeneca.for Adjuvant Treatment of Early Prostate Cancer

    Jul 1, 2004, 00:00

  • Cost–Utility of Adjuvant High-Dose Interferon Alpha Therapy in Stage III Cutaneous Melanoma in Quebec

    Jul 1, 2004, 00:00

  • Patient Preference and Willingness-to-Pay for Humalog Mix25 Relative to Humulin 30/70- A Multicountry Application of a Discrete Choice Experiment

    Jul 1, 2004, 00:00

  • Response to Concerns Regarding the ISPOR Code of Ethics for Researchers

    Jul 1, 2004, 00:00

  • Costs and Benefits of Influenza Vaccination and Work Productivity in a Colombian Company from the Employer's Perspective

    Jul 1, 2004, 00:00

  • Erratum

    Jul 1, 2004, 00:00

  • The Economic Impact of Payer Policies after the Rx-to-OTC Switch of Second-Generation Antihistamines

    Jul 1, 2004, 00:00

  • In Memoriam- Bernie O'Brien (1959–2004)

    Jul 1, 2004, 00:00

  • Cost-Effectiveness of Low-Level Heat Wrap Therapy for Low Back Pain

    Jul 1, 2004, 00:00

  • Discounting Health Outcomes in Economic Evaluation- The Ongoing Debate

    Jul 1, 2004, 00:00

  • Concerns Regarding the ISPOR Code of Ethics for Researchers

    Jul 1, 2004, 00:00

  • Impact of Anemia on Hospitalization Time, Charges, and Mortality in Patients with Heart Failure

    Jul 1, 2004, 00:00

  • The Construct and Concurrent Validity of the EQ-5D in a Renal Transplant Population

    Jul 1, 2004, 00:00

  • The Impact of Urinary Urgency and Frequency on Health-Related Quality of Life in Overactive Bladder- Results from a National Community Survey

    Jul 1, 2004, 00:00

  • Development of a Parametric Simulation Model for Forecasting Goal-Oriented Treatment Outcomes

    Jul 1, 2004, 00:00

  • Estimating a Preference-Based Single Index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) Instrument from the SF-6D

    Jul 1, 2004, 00:00

  • PMH44 REMISSION OF PSYCHOTIC SYMPTOMS AND LONG-TERM FUNCTIONAL OUTCOMES IN THE TREATMENT OF SCHIZOPHRENIA IN USUAL CARE

    May 1, 2004, 00:00

  • PNL8 TRIPTANS IN THE ACUTE TREATMENT OF MIGRAINE- COSTEFFECTIVENESS ANALYSIS BASED ON NUMBER NEEDED TO TREAT AND DOSES NEEDED TO TREAT

    May 1, 2004, 00:00

  • PBR6 REPORT FROM THE FIRST MULTIDISCIPLINARY COST OF BLOOD CONSENSUS (COBCON) WORKING GROUP TO ESTABLISH STANDARD METHODOLOGY

    May 1, 2004, 00:00

  • PDB3 EVALUATION OF PHARMACIST INTERVENTIONS IN DIABETIC PATIENTS FROM RURAL COMMUNITY HEALTH CENTERS

    May 1, 2004, 00:00

  • PCV19 GENDER AND STATIN THERAPY COST AND EFFICACY

    May 1, 2004, 00:00

  • PAA17 THE ASSOCIATION BETWEEN ADHERENCE, ASTHMA CONTROL, GENERIC AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN ASTHMA

    May 1, 2004, 00:00

  • PMH1 EFFECT OF ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PMH72 MEDICATION PRESCRIBING PATTERNS FOR PATIENTS WITH BIPOLAR DEPRESSION

    May 1, 2004, 00:00

  • PCV17 A COST-UTILITY ANALYSIS OF LOSARTAN VERSUS ATENOLOL IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION

    May 1, 2004, 00:00

  • PCN30 USING THE DIFFERENCE IN DIFFERENCE METHOD TO UNDERSTAND OUTCOMES IN PROSTATE CANCER

    May 1, 2004, 00:00

  • PMH57 THE EFFECT OF BEHAVIORAL CARVE-OUTS ON PHARMACEUTICAL USE AND EXPENDITURES

    May 1, 2004, 00:00

  • PHP1 A COST MINIMIZATION ANALYSIS OF FOMEPIZOLE VERSUS ETHANOL WITH OR WITHOUT HEMODIALYSIS IN THE ACUTE MANAGEMENT OF METHANOL OR ETHYLENE-GLYCOL POISONING

    May 1, 2004, 00:00

  • AR4 THE DEVELOPMENT OF PROPENSITY SCORES FROM ADMINISTRATIVE DATABASES FOR THE ANALYSIS OF THE EFFECTIVENESS OF AN OSTEOARTHRITIS ACADEMIC DETAILING SERVICE ON PRESCRIBING BEHAVIOUR

    May 1, 2004, 00:00

  • PMD21 A DESCRIPTIVE ANALYSIS TO INVESTIGATE THE DIFFERENCES BETWEEN TRADERS AND NON-TRADERS IN TIME TRADE OFF

    May 1, 2004, 00:00

  • PMH36 THE COSTS OF POLY-PHARMACY, NON-DRUG TREATMENT, NUMBER OF DRUGS AND SWITCHING FOR BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PMH21 RELATIONSHIP BETWEEN QUETIAPINE DOSE AND LEVELS OF MENTAL HEALTH RESOURCE USE AMONG PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PCV43 EVALUATION OF THE ASSOCIATION BETWEEN HEALTH-RELATED UTILITY AND OBESITY IN HOSPITAL TREATED SUBJECTS

    May 1, 2004, 00:00

  • PMD5 TRACING THE DIFFUSION OF COST-UTILITY ANALYSIS AS AN INNOVATION

    May 1, 2004, 00:00

  • MH1 AN ECONOMIC ANALYSIS OF ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PES18 THE IMPACT OF THE SYSTEM TO MANAGE ACCUTANERELATED TERATOGENICITYTM (SMARTTM) RISK MANAGEMENT PROGRAM ON ISOTRETINOIN PRESCRIBING TRENDS

    May 1, 2004, 00:00

  • PNL24 DEVELOPING A COMPUTER ALGORITHM TO IDENTIFY EPILEPSY CASES IN MANAGED CARE ORGANIZATIONS AND ESTIMATE PREVALENCE, INCIDENCE, AND MORTALITY

    May 1, 2004, 00:00

  • PPN4 EXAMINATION OF TOTAL HEALTH CARE EXPENDITURES FOR PATIENTS ON LONG ACTING OPIOID MEDICATIONS FOR THE TREATMENT OF CHRONIC PAIN IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PDB18 INCREASED HEALTH EXPENDITURES AMONG DIABETES PATIENTS ON INSULIN WITH HYPOGLYCEMIA

    May 1, 2004, 00:00

  • PIN3 OUTCOMES FOLLOWING THE USE OF AZITHROMYCIN OR CLARITHROMYCIN FOR RESPIRATORY TRACT INFECTIONS IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PCV55 DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERCHOLESTEROLAEMIA

    May 1, 2004, 00:00

  • PMH56 MENTAL HEALTH SERVICES AND DRUG UTILIZATION PATTERNS FOR STUDENTS WITH MENTAL ILLNESSES IN SCHOOL-BASED HEALTH CENTERS

    May 1, 2004, 00:00

  • PES5 THE COST-EFFECTIVENESS OF OTOTOPICAL CIPROFLOXACIN AND DEXAMETHASONE VERSUS OTOTOPICAL OFLOXACIN FOR THE TREATMENT OF OTORRHEA IN PATIENTS WITH TYMPANOSTOMY TUBES

    May 1, 2004, 00:00

  • PCV5 PREDICTORS OF ADHERENCE WITH CONCOMITANT ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY

    May 1, 2004, 00:00

  • PHP23 PHARMACEUTICAL PRESCRIPTION- COSTS AND FACTORS OF INFLUENCE

    May 1, 2004, 00:00

  • PCV9 LIPID MANAGEMENT AND FACTORS AFFECTING GOAL ATTAINMENT IN LATIN AMERICA

    May 1, 2004, 00:00

  • PHP21 E-COMMERCE ON PHARMACEUTICALS- A POSITIVE TREND OR A TECHNOLOGICAL DEAMON?

    May 1, 2004, 00:00

  • OP4 DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED USEFULNESS SCALE TO EVALUATE ANTIEPILEPTIC PHARMACOTHERAPY IN PATIENTS WITH EPILEPSY

    May 1, 2004, 00:00

  • PHP3 HANDGUN INJURIES TO CHILDREN AND TEENS RESULTING IN HOSPITALIZATION- CIRCUMSTANCES, RESOURCE USE AND COSTS

    May 1, 2004, 00:00

  • PCV48 OBESITY AMONG HIGH SCHOOL STUDENT AND CONTRIBUTING FACTORS

    May 1, 2004, 00:00

  • PCN12 ECONOMIC BURDEN OF PANCREATIC CANCER AND TREATMENT FAILURE

    May 1, 2004, 00:00

  • PIN19 THE COST-EFFECTIVENESS ANALYSIS OF COMBINATION OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS COMBINATION OF PEGINTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND

    May 1, 2004, 00:00

  • PDB6 GENDER DISPARITY IN THE MANAGEMENT OF DYSLIPIDEMIA AMONG TYPE 2 DIABETES PATIENTS IN A MANAGED-CARE SETTING

    May 1, 2004, 00:00

  • PCV2 COMBINED LIPID GOAL ATTAINMENT IN THE MANAGED CARE SETTING

    May 1, 2004, 00:00

  • PMH59 ANTIPSYCHOTIC ADHERENCE AMONG CENTRAL TEXAS VETERANS

    May 1, 2004, 00:00

  • PCV16 DIFFERENCES IN RESOURCE UTILIZATION IN POST-MI PATIENTS WITH AND WITHOUT HEART FAILURE

    May 1, 2004, 00:00

  • PCV27 HOSPITALIZATION COSTS AND LENGTH OF STAY IN POST-MI PATIENTS WITH HEART FAILURE

    May 1, 2004, 00:00

  • PDB27 HOSPITALIZATIONS WITHIN THE VA AMONG VETERANS WITH DIABETES

    May 1, 2004, 00:00

  • PCN20 PRELIMINARY ECONOMIC ANALYSIS OF THE AMERICAN CANCER SOCIETY GUIDELINES FOR MAMMOGRAPHY SCREENING IN AVERAGE-RISK WOMEN UNDER 70 YEARS OF AGE

    May 1, 2004, 00:00

  • PCV30 COST-EFFECTIVENESS OF STATINS IN CARDIOVASCULAR RISK MANAGEMENT- SYSTEMATIC REVIEW

    May 1, 2004, 00:00

  • PNL20 UTILIZATION OF IMMUNOMODULATORY DRUG THERAPIES IN MULTIPLE SCLEROSIS (MS) IN NOVA SCOTIA, CANADA 1998-2003

    May 1, 2004, 00:00

  • PAR6 COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

    May 1, 2004, 00:00

  • PMH73 DEPRESSION IN THE GENERAL POPULATION AND AFTER STROKE- A PSYCHOMETRIC COMPARISON USING THE CES-D SCALE

    May 1, 2004, 00:00

  • PAA19 CONSUMER SATISFACTION WITH ASTHMA TREATMENT-WHAT MATTERS?

    May 1, 2004, 00:00

  • PES8 ECONOMIC RESOURCES UTILIZED IN A COHORT OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD)

    May 1, 2004, 00:00

  • PMD18 REAL-LIFE PATIENT REPORTED OUTCOMES- DATA MINING OF CONSUMER SPONTANEOUS REPORTS FOR TWO STATINS

    May 1, 2004, 00:00

  • PMD25 ELICITING WILLINGNESS TO PAY WITHIN THE HEALTH SECTOR WITHOUT BIAS

    May 1, 2004, 00:00

  • PMH54 WORK LOSS ASSOCIATED WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PCV33 COST ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM FOR ANTI-OBESITY THERAPY IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PES14 MEDICATION AND HEALTH CARE SERVICE UTILIZATION RELATED TO DEPRESSIVE SYMPTOMS IN OLDER ADULTS WITH PSORIASIS

    May 1, 2004, 00:00

  • PDB8 THE ROLE OF INTRAOPERATIVE PARATHYROID HORMONE MONITORING FOR PARATHYROID HYPERPLASIA

    May 1, 2004, 00:00

  • PMH66 COMPARISON OF FIRST REFILL RATES AMONG BRANDED SSRI USERS

    May 1, 2004, 00:00

  • PIN26 MENINGOCOCCAL VACCINE IN PORTUGAL-A COST-EFFECTIVENESS ANALYSIS

    May 1, 2004, 00:00

  • PCV35 VALIDATION OF THE EQ-5D QUESTIONNAIRE IN PATIENTS WITH A HISTORY OF ACUTE CORONARY SYNDROME

    May 1, 2004, 00:00

  • PAR13 BURDEN OF OSTEOARTHRITIS AND ITS TREATMENT ON PATIENTS

    May 1, 2004, 00:00

  • ND4 BURDEN OF ILLNESS IN ALZHEIMERS DISEASE IN THE UNITED KINGDOM

    May 1, 2004, 00:00

  • PNL3 PREDICTORS OF LOST PRODUCTIVITY AMONG EMPLOYEES WITH MIGRAINE HEADACHES IN A MEDICAL GROUP SETTING- IMPLICATIONS FOR WORKSITE DISEASE MANAGEMENT PROGRAMS

    May 1, 2004, 00:00

  • SC1 COST EFFECTIVENESS OF SCREENING AND STATIN THERAPY IN CLINICAL GUIDELINES FOR CARDIOVASCULAR PROPHYLAXIS

    May 1, 2004, 00:00

  • PMD28 USING A WEB-PANEL TO AID DEFINITION OF A TARGET PATIENT POPULATION TO ASSIST RISK MANAGEMENT

    May 1, 2004, 00:00

  • PMH8 SWITCHING DISCONTINUATION OF SERTRALINE, PAROXETINE AND CITALOPRAM THERAPY

    May 1, 2004, 00:00

  • PAR14 CONTRIBUTION OF PAIN, SITE OF PAIN AND NUMBER OF JOINTS AFFECTED ON PRODUCTIVITY LOSS AMONG WORKERS AND NON-WORKERS WITH OSTEOARTHRITIS

    May 1, 2004, 00:00

  • PMH16 OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER- DETERMINANTS OF CHANGE IN SEVERITY OF BIPOLAR ILLNESS RATINGS

    May 1, 2004, 00:00

  • PCV38 HEALTH-RELATED QUALITY OF LIFE IN AN ACUTE CORONARY SYNDROME POPULATION IS AFFECTED BY DEPRESSION TREATMENT ADEQUACY

    May 1, 2004, 00:00

  • PHP38 AN ASSESSMENT OF THE EFFECT OF DEMOGRAPHICAL AND SOCIOLOGICAL FACTORS ON INDIVIDUAL RESPONSE TO DIRECT-TO-CONSUMER ADVERTISING OF PRESCRIPTION DRUGS

    May 1, 2004, 00:00

  • PCN19 THE COST-EFFECTIVENESS ANALYSIS RECOMBINANT HUMAN ERYTHROPOIETIN GROWTH FACTORS VS. TRANSFUSION IN CHEMOTHERAPY CANCER PATIENTS

    May 1, 2004, 00:00

  • PIN17 COST-EFFECTIVENESS MODELING OF TREATMENT APPROACHES TO HEPATITIS C- A MANAGED CARE PERSPECTIVE

    May 1, 2004, 00:00

  • PMD3 INCREMENTAL COST EFFECTIVENESS RATIOS AND CONFIDENCE INTERVALS-RELATIONSHIP OF CALCULATIONS WITH NNT VERSUS BOOTSTRAP METHODS

    May 1, 2004, 00:00

  • CV4 LOWER CARDIOVASCULAR RISK ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY COMPARED TO INSULIN MONOTHERAPY- A RETROSPECTIVE PROPENSITY SCORE MATCHED COHORT STUDY

    May 1, 2004, 00:00

  • PES12 ESTIMATE OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE USE OF CONVENTIONAL SYSTEMIC AGENTS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS

    May 1, 2004, 00:00

  • PMD20 PRO INSTRUMENT DEVELOPMENT FOR RARE DISORDERS- A FOCUS-ED APPROACH

    May 1, 2004, 00:00

  • PCV21 PREVALENCE AND COST IMPLICATIONS OF POTENTIAL INTERACTIONS WITH STATIN MEDICATIONS IN A MANAGED CARE POPULATION

    May 1, 2004, 00:00

  • PCV8 WARFARIN ANTICOAGULATION AND OUTCOMES IN ATRIAL FIBRILLATION PATIENTS-A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2004, 00:00

  • PMD12 MEDICATION COMPLIANCE AND CONCOMITANT THERAPY

    May 1, 2004, 00:00

  • PMD8 HAZARD ISOBARS- A NEW, POLICY-ORIENTED TOOL FOR INTEGRATING INFORMATION FROM COX PROPORTIONAL HAZARD MODELS INTO COST-EFFECTIVENESS SIMULATIONS

    May 1, 2004, 00:00

  • PMH17 ANTIDEPRESSANT MONOTHERAPY AND OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PNL16 FACTORS THAT DETERMINE EMPLOYABILITY IN EPILEPSY PATIENTS- A PILOT STUDY

    May 1, 2004, 00:00

  • PMH42 CORRELATIONS BETWEEN PSYCHOPATHOLOGY AND HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN SCHIZOPHRENIA. RESULTS FROM THE SQUARE STUDY

    May 1, 2004, 00:00

  • PNL19 VALIDATION OF THE HUNTER SYNDROME-FUNCTIONAL OUTCOMES FOR CLINICAL UNDERSTANDING SCALE (HS-FOCUS)

    May 1, 2004, 00:00

  • PDB9 POTENTIAL MEDICAL COST REDUCTION DUE TO DECREASES IN A1C RESULTING FROM PHARMACIST DIABETES EDUCATON AND MEDICATION RECOMMENDATIONS IN A COMMUNITY SETTING

    May 1, 2004, 00:00

  • PHP10 EQUITY IN THE NATIONAL HEALTH INSURANCE DURING ECONOMIC RECESSION- MISSION IMPOSSIBLE?

    May 1, 2004, 00:00

  • PHP19 COMPARING THE COSTS OF MAIL ORDER AND RETAIL PHARMACY

    May 1, 2004, 00:00

  • PCV11 EVALUATING CLINICAL OUTCOMES FOR SUBJECTS THAT ARE NEWLY INITIATED ON HMG-COA REDUCTASE INHIBITORS IN A NATURALISTIC ENVIRONMENT USING LONGITUDINAL DESIGN

    May 1, 2004, 00:00

  • Abstracts Index

    May 1, 2004, 00:00

  • PCV39 HEALTH STATUS IN HIGH-RISK PATIENTS UNDERGOING NONCARDIAC VASCULAR SURGERY IN THE UNITED STATES

    May 1, 2004, 00:00

  • PNL6 COMPARISON OF CLINICAL EFFICACY AND COSTEFFECTIVENESS BETWEEN ELETRIPTAN 40MG AND SUMATRIPTAN 100MG IN THE ACUTE TREATMENT OF MIGRAINE

    May 1, 2004, 00:00

  • CN2 7215 COST-EFFECTIVENESS OF DIAGNOSTIC, STAGING, AND TREATMENT OPTIONS FOR MELANOMA

    May 1, 2004, 00:00

  • HP1 EVALUATION OF GENERIC DISPENSING INCENTIVE PROGRAM (GDIP)

    May 1, 2004, 00:00

  • PMD13 ADHERENCE INDEX- A NEW AND IMPROVED APPROACH TO MEASURE MEDICATION COMPLIANCE

    May 1, 2004, 00:00

  • PHP17 RECENT TRENDS IN INPATIENT DRUG COSTS- 2000-2002

    May 1, 2004, 00:00

  • PCN6 FACTORS INFLUENCING PHYSICIAN RECOMMENDATION FOR IMATINIB MESYLATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) PATIENTS

    May 1, 2004, 00:00

  • AC2 COMPARING PATIENT-REPORTED MEDICATION COMPLIANCE WITH ELECTRONICALLY MONITORED MEDICATION COMPLIANCE IN A 12-MONTH INTERNATIONAL REGISTRY

    May 1, 2004, 00:00

  • AC1 CAPTURING PATIENT-REPORTED COMPLIANCE DATA IN A NINE-COUNTRY PRODUCT REGISTRY USING MEMS CAP DEVICES

    May 1, 2004, 00:00

  • PE1 ASSESSING EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING- DATA FROM AN EFFECTIVENESS STUDY OF ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • PMH24 UTILIZATION ANALYSIS OF HEALTH CARE RESOURCES FOR PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • CE3 THE COSTS OF ADJUVANT CHEMOTHERAPY IN EARLY STAGE BREAST CANCER PATIENTS- COMPARISON OF ATTRIBUTABLE COST AND MICROCOSTING APPROACHES

    May 1, 2004, 00:00

  • PHP1 HOSPITALIZATIONS FOR INJURIES FROM FIREWORKS- RESOURCE USE AND COSTS

    May 1, 2004, 00:00

  • PHP28 PATIENT SATISFACTION-PATIENT EDUCATION INTERFACE

    May 1, 2004, 00:00

  • PIN12 COST-EFFECTIVENESS OF INTRAVENOUS IMMUNOGLOBULIN MANUFACTURED FROM CHROMOTOGRAPHY-CAPRYLATE VS. SOLVENT-DETERGENT METHODS IN PERSONS WITH PRIMARY IMMUNODEFICIENCY DISEASE

    May 1, 2004, 00:00

  • PCN15 DIRECT MEDICAL COSTS OF MANAGING TOXICITIES RELATED TO TAXANE THERAPY FOR METASTATIC BREAST CANCER IN THE UNITED STATES

    May 1, 2004, 00:00

  • PNL11 HEALTH CARE COSTS FOR FLORIDA MEDICAID RECIPIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2004, 00:00

  • PAA11 EFFECTIVENESS AND COST-BENEFIT OF LEUKOTRIENE MODIFIERS IN ADULTS WITH ASTHMA IN THE OHIO MEDICAID POPULATION

    May 1, 2004, 00:00

  • PCV42 PERSISTENCE AND ADHERENCE TO STATIN THERAPY IN A MANAGED CARE SETTING

    May 1, 2004, 00:00

  • PCV57 ASSOCIATION BETWEEN INSURANCE COVERAGE AND OUTCOMES FOR INDIVIDUALS HOSPITALIZED FOR NONHEMORRHAGIC STROKE

    May 1, 2004, 00:00

  • PES1 PATIENTS PERSISTENCE AND ADHERENCE WITH GLAUCOMA THERAPY- A LONGITUDINAL RETROSPECTIVE DATABASE ANALYSIS OF OPHTHALMIC LIPIDS

    May 1, 2004, 00:00

  • PMH76 A COMPREHENSIVE RETROSPECTIVE STUDY OF ASSOCIATIONS BETWEEN DIABETES AND TREATMENT WITH RISPERIDONE, OLANZAPINE, QUETIAPINE, AND CONVENTIONAL ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • PCN13 AN ECONOMIC ANALYSIS OF RADIATION VERSUS RADIATION PLUS GOSERELIN IN THE TREATMENT OF LOCALLY ADVANCED PROSTATE CANCER

    May 1, 2004, 00:00

  • PIN29 THE ECONOMIC EVALUATION OF INFLUENZA VACCINATION IN THE ELDERLY POPULATION- A MODEL BASED ON BAYESIAN NETWORKS

    May 1, 2004, 00:00

  • PCN7 TRENDS IN CHEMOTHERAPY USE, OUTCOMES, AND COST FOR PATIENTS WITH ADVANCED NONSMALL LUNG CANCER- EVIDENCE FROM SEER-MEDICARE

    May 1, 2004, 00:00

  • PMH71 WHEN BIPOLAR DISORDER IS BEING IDENTIFIED- PHASE OF DISORDER, PROVIDER SPECIALTY, FACILITY TYPE, AND RESOURCE UTILIZATION SURROUNDING THE INITIAL BIPOLAR DIAGNOSIS IN CLINICAL PRACTICE

    May 1, 2004, 00:00

  • PDB26 PREFERENCE, EFFICACY, SAFETY AND ACTUAL USE OF BLOOD GLUCOSE (BG) MONITORING WITH INDUO VS SYRINGE AND SEPARATE METER IN SUBJECTS WITH TYPE 1 DIABETES

    May 1, 2004, 00:00

  • PCV24 7309 HEALTH CARE RESOURCE UTILIZATION BY PATIENTS WITH ESSENTIAL HYPERTENSION

    May 1, 2004, 00:00

  • PMH19 ESCITALOPRAM IN THE TREATMENT OF KLEPTOMANIA

    May 1, 2004, 00:00

  • PAA7 HEALTH CARE EXPENDITURES OF PATIENTS WITH COMORBID ALLERGIC RHINITIS AND ASTHMA

    May 1, 2004, 00:00

  • PES2 MEDICATION ADHERENCE RATES AND DISEASE SEVERITY CHANGES IN PSORIASIS

    May 1, 2004, 00:00

  • PAA2 THE PREVALENCE OF INAPPROPRIATE USE OF SHORTACTING ASTHMA MEDICATION

    May 1, 2004, 00:00

  • PES7 A COST-EFFECTIVENESS ANALYSIS OF TREATING OPEN ANGLE GLAUCOMA

    May 1, 2004, 00:00

  • PAR11 REVALIDATION OF THE CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) SHORT FORM INSTRUMENT

    May 1, 2004, 00:00

  • PCV29 COST EFFECTIVENESS ANALYSIS OF THERAPY MODIFICATION AFTER FAILING STATIN TREATMENT

    May 1, 2004, 00:00

  • PMH7 TREATMENT AND ECONOMIC OUTCOMES IN PEDIATRIC INPATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • PIN1 OUTCOMES OF AN INTERACTIVE VOICE RESPONSE (IVR) REMINDER SYSTEM TO PROMOTE MANAGED CARE ORGANIZATION (MCO) MEMBERS ATTAINMENT OF INFLUENZA IMMUNIZATION

    May 1, 2004, 00:00

  • PMH13 USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE DEPRESSION AND ANXIETY POPULATIONS IN FOUR COUNTRIES

    May 1, 2004, 00:00

  • PIN27 THE IMPACT OF PHYSICIAN PROFILING ON ANTIBIOTIC COST AND UTILIZATION

    May 1, 2004, 00:00

  • PCV6 ANALYZING RISK OF BLEEDING IN ADMINISTERING LOW MOLECULAR WEIGHT HEPARINS AND/OR ASPIRIN TO ORTHOPEDIC PATIENTS

    May 1, 2004, 00:00

  • PMD11 CHOOSING AMONG DIFFERENT TYPES OF BOOTSTRAPPING METHODS

    May 1, 2004, 00:00

  • PCV50 GASTRIC BYPASS SURGERY-AN OVERVIEW

    May 1, 2004, 00:00

  • PIN30 OBSERVATIONAL STUDY ON THE 'REAL LIFE' PRACTICE AND COST OF ANTIBIOTIC (AB) MEDICATION IN PNEUMOCOCCAL PNEUMONIA PATIENTS- PARENTERAL VERSUS STEP DOWN THERAPY (SDT)

    May 1, 2004, 00:00

  • PCV1 ZIPRASIDONE VS OLANZAPINE- CONTRASTS IN CHD RISK- PCVI

    May 1, 2004, 00:00

  • PBR5 GREATER AREA UNDER THE HEMOGLOBIN CHANGE CURVE DURING EPOETIN ALFA TREATMENT IS ASSOCIATED WITH IMPROVED PATIENT OUTCOMES

    May 1, 2004, 00:00

  • PNL1 HOW COGNITIVE FUNCTION AFFECTS ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ALZHEIMERS DISEASE

    May 1, 2004, 00:00

  • PAA10 BUDGET IMPACT ANALYSIS- COMBINATION FLUTICASONE AND SALMETEROL FOR ASTHMA

    May 1, 2004, 00:00

  • RX3 EVALUATING CLINICAL AND FINANCIAL OUTCOMES ASSOCIATED WITH A RETROSPECTIVE DRUG UTILIZATION REVIEW PROGRAM

    May 1, 2004, 00:00

  • PAR15 ETHNIC VARIATIONS IN PREFERENCE FOR TOTAL KNEE REPLACEMENT IN PATIENTS WITH OSTEOARTHRITIS

    May 1, 2004, 00:00

  • PDB12 ESTIMATING THE REDUCTION IN LONG TERM COMPLICATION AND COSTS OF COMPLICATIONS IN TYPE 1 DIABETES BY REDUCED A1C LEVELS DUE TO MORE FREQUENT BLOOD GLUCOSE MONITORING

    May 1, 2004, 00:00

  • MH4 ASSESSMENT OF HEALTH STATE UTILITIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN USING PARENT-BASED STANDARD GAMBL SCORES

    May 1, 2004, 00:00

  • PNL2 OXCARBAZEPINE REDUCES HOSPITALISATIONS FOR EPILEPTIC SEIZURES AND RELATED SYMPTOMS IN THE NETHERLANDS- A PHARMO STUDY

    May 1, 2004, 00:00

  • PAR5 COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRATM) IN THE TREATMENT OF US PATIENTS WITH RHEUMATOID ARTHRITIS (RA)

    May 1, 2004, 00:00

  • PNL7 A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT COSTS OF MIGRAINE AND ITS COMORBID CONDITIONS IN TAIWAN

    May 1, 2004, 00:00

  • PHP42 METHODS FOR 'GO/NO-GO' MODELING OF COMPOUNDS IN THE DEVELOPMENT PIPELINE

    May 1, 2004, 00:00

  • PMH48 ASSESSMENT OF THE IMPACT OF QUETIAPINE TREATMENT ON PSYCHOPATHOLOGY, HEALTH RELATED QUALITY OF LIFE AND DISABILITY IN PATIENTS WITH SCHIZOPHRENIA IN GREECE.THE SQUARE STUDY

    May 1, 2004, 00:00

  • PGI11 RETROSPECTIVE ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM USING COX-2 INHIBITORS IN A MANAGED CARE POPULATION

    May 1, 2004, 00:00

  • PHP11 ESTIMATING THE ABILITY-TO-PAY FOR HEALTH CARE EXPENDITURES RISING FASTER THAN GDP- AN INTERNATIONAL PERSPECTIVE COMPARING THE USA AND GERMANY

    May 1, 2004, 00:00

  • PCN10 THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR BASAL CELL CARCINOMA

    May 1, 2004, 00:00

  • PES4 COST-UTILITY OF COCHLEAR IMPLANTS A SOCIETAL PERSPECTIVE ANALYSIS

    May 1, 2004, 00:00

  • PAR16 TRENDS IN THE USE OF PATIENT REPORTED OUTCOMES IN OSTEOARTHRITIS CLINICAL TRIALS AND SUBSEQUENT PRODUCT LABELS

    May 1, 2004, 00:00

  • PES9 ELIGIBILITY, UTILIZATION, AND COSTS IN A CALIFORNIA MEDICAID LUPUS POPULATION

    May 1, 2004, 00:00

  • PMD17 USING AN ARTIFICIAL NEURAL NETWORK TO PREDICT UTILITY SCORES FROM SF-36 DATA

    May 1, 2004, 00:00

  • PIN6 TAMPON-RELATED TOXIC SHOCK SYNDROME (TSS) CONTINUES TO PEAK AMONG ADOLESCENT GIRLS- A NATIONWIDE HOSPITAL STUDY

    May 1, 2004, 00:00

  • PPN2 THE DIRECT AND INDIRECT ECONOMIC IMPACT OF PAIN AND ITS COMPARISON WITH THREE OF THE TOP FIVE MOST COSTLY DISEASES

    May 1, 2004, 00:00

  • PHP27 INFLATION- PRESCRIPTION DRUG MARKET BASKET DEFINITION AND THEIR IMPACT

    May 1, 2004, 00:00

  • PHP24 QUALITY OF DECISION-MAKING BY THE PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) AND THE IMPACT ON OUTCOMES

    May 1, 2004, 00:00

  • PCV7 EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PRIMARY CARE IN FRANCE

    May 1, 2004, 00:00

  • PCN18 COST ANALYSIS OF LUNG CANCER TREATMENT IN TAIWAN

    May 1, 2004, 00:00

  • PGI2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF TOTAL AND PARTIAL LAPAROSCOPIC FUNDOPLICATION FOR THE TREATMENT OF GORD

    May 1, 2004, 00:00

  • PIN5 A META-ANALYSIS OF THREE-DAY AZITHROMYCIN THERAPY VERSUS LONGER COURSES OF COMPARATOR ANTIBIOTICS IN ACUTE SINUSITIS

    May 1, 2004, 00:00

  • CV3 THE USE OF A PROBABILISTIC DECISION MODEL TO ASSESS THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS IN ALTERNATIVE PATIENT SUB-GROUPS

    May 1, 2004, 00:00

  • PCV28 AN ARB COST-EFFECTIVENESS MODEL IN TREATING MILD-TO-MODERATE HYPERTENSION

    May 1, 2004, 00:00

  • PMH69 PATTERNS OF PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PDB22 THE VALUE TO HIGH-RISK PATIENTS OF PREVENTING A CASE OF DIABETES

    May 1, 2004, 00:00

  • PCN11 COST-EFFECTIVENESS ANALYSIS OF DOSE-DENSE CHEMOTHERAPY WITH FILGRASTIM AS POSTOPERATIVE ADJUVANT TREATMENT OF BREAST CANCER

    May 1, 2004, 00:00

  • PDB16 THE ECONOMIC AND HEALTH OUTCOMES OF USING DIFFERENT INSULIN DELIVERY DEVICES IN A MANAGED CARE ENVIRONMENT

    May 1, 2004, 00:00

  • PNL22 THE SENSITIVITY OF COST-EFFECTIVENESS ESTIMATES IN MULTIPLE SCLEROSIS TO INTERNATIONAL DIFFERENCES IN NATURAL HISTORY- SWEDEN VERSUS NOVA SCOTIA, CANADA

    May 1, 2004, 00:00

  • PCN2 IMPACT OF CHEMOTHERAPY-INDUCED DIARRHEA ON MANAGEMENT PATTERNS AND RESOURCE UTILIZATION AMONG CANCER PATIENTS- RESULTS FROM A MULTI-SITE STUDY

    May 1, 2004, 00:00

  • PIN4 EXAMINATION OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATION

    May 1, 2004, 00:00

  • PES10 THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR DIFFICULT TO TREAT ACTINIC KERATOSES

    May 1, 2004, 00:00

  • OP2 COMPARISON OF DISCRETE CHOICE EXPERIMENT (DCE) WITH VISUAL ANALOG SCALING (VAS) METHODS FOR ESTIMATING PREFERENCES FOR PHYSICAL DISABILITY STATES

    May 1, 2004, 00:00

  • PCV51 RETROSPECTIVE EVALUATION OF UTILIZATION PATTERNS OF BETA-BLOCKER THERAPY IN CONGESTIVE HEART FAILURE PATIENTS IN A MANAGED CARE ENVIRONMENT

    May 1, 2004, 00:00

  • PPN9 PRESCRIPTION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND MUSCLE RELAXANTS FOR BACK PAIN IN THE UNITED STATES

    May 1, 2004, 00:00

  • PCV31 ECONOMIC ANALYSIS OF AMIODARONE, ATRIAL SEPTAL PA CING, AMIODARONE PLUS ATRIAL SEPTAL PACING VERSUS STANDARD OF CARE TO PREVENT ATRIAL FIBRILLATION AFTER OPEN-HEART SURGERY

    May 1, 2004, 00:00

  • PMH67 DEPRESSION DIAGNOSIS IN PRIMARY CARE VISITS NOT FOR MENTAL HEALTH REASONS

    May 1, 2004, 00:00

  • PHP15 INCLUDING CARER UTILITY IN ECONOMIC EVALUATIONS- A PRELIMINARY ANALYSIS OF THE IMPLICATIONS FOR FUNDING THRESHOLDS

    May 1, 2004, 00:00

  • PCN4 TECHNOLOGY ADVANCES AND TREATMENT PATTERN VARIATIONS IN ONCOLOGY- EVIDENCE FROM USE OF CPT-11 IN ELDERLY METASTATIC COLORECTAL CANCER PATIENTS

    May 1, 2004, 00:00

  • PIN34 THE USE OF ANTIBIOTICS TO TREAT ACUTE UPPER RESPIRATORY TRACT INFECTIONS IN A STATE MEDICAID POPULATION

    May 1, 2004, 00:00

  • ND1 ESTIMATING COST-EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS USING NET BENEFIT REGRESSION MODEL METHODS

    May 1, 2004, 00:00

  • PPN3 AN EVALUATION OF THE DIRECT COSTS OF ADVERSE GI EVENTS ASSOCIATED WITH THE USE OF NSAIDS IN THE UNITED STATES

    May 1, 2004, 00:00

  • PMH43 DIFFERENTIAL IMPACT OF OLANZAPINE AND RISPERIDONE ON SEXUAL DYSFUNCTION AND ITS POTENTIAL IMPLICATIONS

    May 1, 2004, 00:00

  • PNL13 A COMPARATIVE COST ANALYSIS OF VASCULAR DEMENTIA VERSUS ALZHEIMERS DISEASE IN TAIWAN

    May 1, 2004, 00:00

  • PDB11 DIFFERENCES IN HYPOGLYCEMIA EVENT RATES AND ASSOCIATED COST-CONSEQUENCE IN PATIENTS INITIATED ON LONG-ACTING AND INTERMEDIATE-ACTING INSULIN PRODUCTS

    May 1, 2004, 00:00

  • POS1 THE INFLUENCE OF BONE MINERAL DENSITY TESTING ON THE INITIATION OF AN OSTEOPOROSIS-RELATED PHARMACOTHERAPY- A POPULATION-BASED ANALYSIS

    May 1, 2004, 00:00

  • PMH37 COST CONSEQUENCE ASSOCIATED WITH DIFFERENT INITIAL MOOD STABILIZERS FOR NEWLY TREATED PATIENTS WITH BIPOLAR DISORDERS

    May 1, 2004, 00:00

  • PCV12 UTILIZATION PATTERNS OF HYPERTENSION THERAPIES AMONG PATIENTS INITIATING ANGIOTENSION II RECEPTOR ANTAGONIST THERAPY

    May 1, 2004, 00:00

  • POS2 DIFFERENCES BETWEEN DOCTOR AND PATIENT RECALL OF EVENTS IN AND INVESTIGATIONS FOR OSTEOPOROSIS IN FIVE COUNTRIES

    May 1, 2004, 00:00

  • PUK9 ECONOMIC IMPACT OF EPOETIN ALFA (EPO) TREATMENT AMONG NON-DIALYSIS CHRONIC KIDNEY DISEASE (NDCKD) PATIENTS WITH ANEMIA

    May 1, 2004, 00:00

  • PMH77 ORDERING EFFECTS IN CROSSOVER STUDIES OF PHOTOTHERAPY- IMPLICATIONS FOR PSYCHOLOGICAL INTERVENTIONS

    May 1, 2004, 00:00

  • PMD23 WHAT IS THE VALUE OF SOCIAL VALUES? THE USELESSNESS OF ASSESSING HEALTH-RELATED QUALITY OF LIFE THROUGH PREFERENCE MEASURES

    May 1, 2004, 00:00

  • PCN27 THE BREAST CANCER SCREENING RATES OF GEORGIA MEDICAID RECIPIENTS

    May 1, 2004, 00:00

  • PUK3 DITROPAN XL PROVIDES SUPERIOR OUTCOMES AND LOWER COSTS COMPARED TO DETROL LA

    May 1, 2004, 00:00

  • PGI3 COST-UTILITY ANALYSIS COMPARING ESOMEPRAZOLE WITH THE ORO-DISPERSIBLE FORMULATION OF LANSOPRAZOLE IN THE INITIAL TREATMENT OF REFLUX OESOPHAGITIS

    May 1, 2004, 00:00

  • PCV47 THE NATIONAL ANTICOAGULATION BENCHMARK AND OUTCOMES REPORT (NABORTM)- EVIDENCE OF A SIGNIFICANT DIFFERENCE BETWEEN GUIDELINES AND ACTUAL PRACTICE

    May 1, 2004, 00:00

  • PMD2 MONTE-CARLO VALIDATION OF DELTA-K METHOD FOR SAMPLE-SIZE CALCULATION IN A COST-EFFECTIVENESS TRIAL

    May 1, 2004, 00:00

  • PMH20 RISK OF REHOSPITALIZATION- OLANZAPINE VERSUS QUETIAPINE

    May 1, 2004, 00:00

  • PCV22 COST AND COMORBIDITIES ASSOCIATED WITH ATRIAL FIBRILLATION IN DIFFERENT AGE GROUPS

    May 1, 2004, 00:00

  • POS6 TERIPARATIDE VERSUS BISPHOSPHONATES IN HIGH RISK OSTEOPOROSIS PATIENTS- A DECISION MODEL ANALYSIS

    May 1, 2004, 00:00

  • PAA18 THE ASSOCIATION BETWEEN MEASURES OF HEALTH STATE UTILITIES, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA

    May 1, 2004, 00:00

  • DB3 OUTCOMES ASSOCIATED WITH THE INTRODUCTION OF THIAZOLIDINEDIONE THERAPY IN ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS- A RETROSPECTIVE DATA ANALYSIS

    May 1, 2004, 00:00

  • PGI7 FECAL LACTOFERRIN ASSAY FOR THE INITIAL DIAGNOSTIC APPROACH TO SYMPTOMATIC PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS-A COST-EFFECTIVENESS ANALYSIS

    May 1, 2004, 00:00

  • PMH27 DIRECT HEALTH CARE COST OF DEPRESSIVE DISORDERSIN THE UNITED STATES- A PATIENT TIME PROFILE

    May 1, 2004, 00:00

  • PCV32 USE OF ANTILIPEMIC DRUGS IN NATIONAL HEALTH CARE GROUP (NHG), SINGAPORE

    May 1, 2004, 00:00

  • PBR4 BLOOD DONATION IN THE 21ST CENTURY- MOTIVATION AMIDST CRISIS

    May 1, 2004, 00:00

  • PMH79 STATISTICALLY DETERMINING TREATMENT OF CHOICE FOR INDIVIDUAL PATIENTS WITH SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PDB15 TOTAL CHOLESTEROL, HDL CHOLESTEROL AND HBA1C AFFECT QUALITY-ADJUSTED LIFE YEARS AND HOSPITAL COSTS FOR PATIENTS WITH TYPE 2 DIABETES IN THE UNITED KINGDOM-THE CARDIFF DIABETES COST UTILITY MODEL

    May 1, 2004, 00:00

  • PGI5 COST-EFFECTIVENESS OF TREATING ADULTS WITH CHRONIC HEPATITIS C (CHC) AND PERSISTENTLY NORMAL ALANINE AMINOTRANSFERASE (PNALT) WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS)

    May 1, 2004, 00:00

  • PNL14 HEALTH CARE UTILIZATION AND EXPENDITURES AMONG MEDICAID PATIENTS WITH PARKINSONS DISEASE

    May 1, 2004, 00:00

  • PMH58 THE RELATIONSHIP BETWEEN MENTAL DISTRESS, HEALTH RISKS AND HEALTH CARE COSTS FROM THE MANAGED CARE HEALTH RISK ASSESSMENT DATABASE

    May 1, 2004, 00:00

  • PCN31 WEIGHT OR NOT TO WEIGHT?

    May 1, 2004, 00:00

  • PHP30 PATIENT SATISFACTION WITH HEALTH CARE SERVICES- IDENTIFYING VOIDS

    May 1, 2004, 00:00

  • PES6 PATIENT-REPORTED IMPACT OF AGE-RELATED MACULAR DEGENERATION

    May 1, 2004, 00:00

  • PUK12 PROSPECTIVE URINARY INCONTINENCE RESEARCH (PURE)- DESCRIPTION OF STUDY, RATIONAL, DESIGN AND METHODOLOGY

    May 1, 2004, 00:00

  • PMH45 MAPPING UTILITY SCORES FROM THE EQ-5D AND SF-6D ONTO THE SCHIZOPHRENIA QUALITY OF LIFE SCALE

    May 1, 2004, 00:00

  • PMH28 COST-EFFECTIVENESS OF INTERVENTIONS TO IMPROVE PATIENT MEDICATON COMPLIANCE IN MAJOR DEPRESSIVE DISORDER

    May 1, 2004, 00:00

  • PIN22 HOSPITAL UTILIZATION TRENDS OF HIV DISEASE IN THE UNITED STATES, 1993 TO 2001

    May 1, 2004, 00:00

  • PPN8 PATTERNS AND TRENDS IN OPIOID USE AMONG INDIVIDUALS WITH BACK PAIN IN THE UNITED STATES

    May 1, 2004, 00:00

  • PMH34 COST-EFFECTIVENESS OF OLANZAPINE VERSUS LITHIUM FOR THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER IN AUSTRALIA

    May 1, 2004, 00:00

  • PCN23 XEROSTOMIA SYMPTOMS- A NEWLY DEVELOPED PATIENT REPORTED OUTCOMES QUESTIONNAIRE

    May 1, 2004, 00:00

  • PUK6 THE RELATIONSHIP BETWEEN COST OF CARE AND COMORBIDITY IN CHRONIC KIDNEY DISEASE

    May 1, 2004, 00:00

  • PPN1 ANTICIPATED PAIN PRIOR TO SURGERY COMPARED TO ACTUAL PAIN IN PATIENTS UNDERGOING OUTPATIENT ARTHROSCOPIC KNEE PROCEDURES

    May 1, 2004, 00:00

  • PHP4 BURDEN OF ILLNESS FOR EMPLOYEES WITH PAINFUL CONDITIONS

    May 1, 2004, 00:00

  • PHP13 WHO BENEFITS FROM OVER-THE-COUNTER (OTC) MEDICATION COVERAGE IN A STATE MEDICAID PROGRAM?

    May 1, 2004, 00:00

  • PMH64 MISDIAGNOSIS OF BIPOLAR DISORDER AS UNIPOLAR DEPRESSION

    May 1, 2004, 00:00

  • ND3 MEDICAL SERVICES UTILIZATION FOR PATIENTS WITH PARKINSONS DISEASE IN A STATE MEDICAID PROGRAM

    May 1, 2004, 00:00

  • PNL4 IMPACT OF MIGRAINE AND NON-MIGRAINE HEADACHES ON EMPLOYEE PRODUCTIVITY IN A MEDICAL GROUP SETTING

    May 1, 2004, 00:00

  • PMH78 IDENTIFICATION OF DEPRESSION IN PATIENTS WITH LOW BACK PAIN- IMPACT OF ELECTRONIC MESSAGING AT THE POINT OF CARE

    May 1, 2004, 00:00

  • PIN9 VARIABILITY IN THE USE OF HIV PHENOTYPIC TESTING BY SPECIALTY OF PRACTITIONER

    May 1, 2004, 00:00

  • PMD22 PATIENT PREFERENCES FOR COMPUTER ASSISTED DATA COLLECTION AT THE CLINICAL INTERFACE

    May 1, 2004, 00:00

  • PHP6 THE SOCIOECONOMIC COST OF DISEASES DUE TO SMOKING IN KOREA

    May 1, 2004, 00:00

  • PMD14 STUDYING COMPLIANCE WITH MEDICATION IN CHRONIC ILLNESSES USING ADMINISTRATIVE DATA- INTRACTABLE CALENDAR TRENDS?

    May 1, 2004, 00:00

  • PES13 FACTORS AFFECTING HEALTH CARE EXPENDITURES AMONG PATIENTS WITH DERMATOPHYTOSIS

    May 1, 2004, 00:00

  • PMH2 GAPS IN ANTIPSYCHOTIC MEDICATION AND RISK OF HOSPITALIZATION FOR THE TREATMENT OF SCHIZOPHRENIA IN MANAGED CARE SETTINGS

    May 1, 2004, 00:00

  • PHP29 CONSUMER SATISFACTION WITH HEALTH PLANS AND DRUG BENEFIT MANAGEMENT STRATEGIES

    May 1, 2004, 00:00

  • PNL15 AN ECONOMIC ANALYSIS OF CALCIUM CHANNEL BLOCKERS FOR ACUTE TRAUMATIC BRAIN INJURY

    May 1, 2004, 00:00

  • PCV20 RATES OF HYPERTENSION-RELATED MEDICAL AND PRESCRIPTION UTILIZATION AND COSTS IN A STATE MEDICAID POPULATION

    May 1, 2004, 00:00

  • PMH70 PHARMACOLOGIC TREATMENT PATTERNS FOR BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PMD7 REGRESSION-BASED STATISTICAL MODEL AND PROPENSITY SCORE METHODS FOR THE EVALUATION OF COSTEFFECTIVENESS STUDIES

    May 1, 2004, 00:00

  • OP3 UNDERSTANDING THE CHARACTERISTICS OF NON TRADERS IN TTO UTILITY ELICITATION

    May 1, 2004, 00:00

  • PMH49 USING CLIENT AND STAFF STRUCTURED INPUT IN FORMATTING THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP) SURVEY

    May 1, 2004, 00:00

  • PCN14 AN ECONOMIC EVALUATION OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A US HEALTH CARE PERSPECTIVE

    May 1, 2004, 00:00

  • PCN32 CENSORED MEDICAL COST ESTIMATION

    May 1, 2004, 00:00

  • PMH68 TRENDS IN PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR- 1992-2002

    May 1, 2004, 00:00

  • PHP5 THE SOCIOECONOMIC COST OF DISEASES IN KOREA

    May 1, 2004, 00:00

  • PDB30 DEVELOPMENT OF A DIABETES RESOURCE CONSUMPTION INDEX (DRCI) USING VETERANS HEALTH ADMINISTRATION DATA

    May 1, 2004, 00:00

  • PMD15 RELIABILITY AND VALIDITY OF THE EQ-5D SELF-REPORT QUESTIONNAIRE IN TAIWAN POPULATION

    May 1, 2004, 00:00

  • PAR8 HEALTH RELATED QUALITY OF LIFE OF CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS PATIENTS RECEIVING FENTANYL TRANSDERMAL SYSTEM

    May 1, 2004, 00:00

  • PMH33 DRUG TREATMENT PATTERNS OF BIPOLAR DISORDER AND ASSOCIATED COSTS

    May 1, 2004, 00:00

  • PCN21 SHORT-TERM PSYCHOSOCIAL COUNSELING FOR PATIENTS WITH NEWLY-DIAGNOSED PROSTATE CANCER

    May 1, 2004, 00:00

  • PDB4 PARTICIPATION IN HOME-BASED A1C TESTING IN CAREPATTERNS PROGRAM FOR DIABETES

    May 1, 2004, 00:00

  • PHP33 FACTORS ASSOCIATED WITH TTO UTILITY CHANGES AMONG OLDER PEOPLE AT VETERAN HOME

    May 1, 2004, 00:00

  • PCV49 DOES THE RATE OF MEDICARE MANAGED-CARE PENETRATION AFFECT AVAILABILITY OF RESOURCES FOR HEART FAILURE TREATMENT?

    May 1, 2004, 00:00

  • PHP31 POTENTIALLY INAPPROPRIATE PRESCRIBING FOR OLDER VETERANS-WHOS AT RISK?

    May 1, 2004, 00:00

  • HM4 HOW ROBUST IS COST-EFFECTIVENESS RATIO TO MISSING DATA IMPUTATION? ANALYSIS OF LONG-TERM CLINICAL TRIAL IN PARKINSONS DISEASE

    May 1, 2004, 00:00

  • PIN7 CHANGES IN HIV ANTIVIRAL PHENOTYPIC DRUG RESISTANCE DURING THE HAART ERA

    May 1, 2004, 00:00

  • PMD6 RESOURCE COSTING IN CLINICAL TRIALS

    May 1, 2004, 00:00

  • PDB2 COMPARISON OF PIOGLITAZONE WITH OTHER ANTIDIABETIC DRUGS FOR ASSOCIATED INCIDENCE OF LIVER FAILURE- NO EVIDENCE OF INCREASED LIVER FAILURE WITH PIOGLITAZONE

    May 1, 2004, 00:00

  • PIN32 ACUTE SINUSITIS IN MANAGED CARE- ANTIBIOTIC TREATMENT AND OUTCOMES

    May 1, 2004, 00:00

  • PMH11 ANTIDEPRESSANT USE AND RISK OF SUICIDE ATTEMPT IN ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER

    May 1, 2004, 00:00

  • PHP41 PARALLEL TRADE OF PHARMACEUTICALS AS A COST-CONTAINMENT MEASURE-ANALYSIS OF THE ISRAELI EXPERIENCE

    May 1, 2004, 00:00

  • RI3 COST-EFFECTIVENESS OF INFLUENZA VACCINE IN 6-24 MONTH OLD CHILDREN

    May 1, 2004, 00:00

  • PUK8 COST-EFFECTIVENESS ANALYSIS OF THE TREATMENT OF URINARY TRACT INFECTIONS IN A COLLEGE-AGE POPULATION

    May 1, 2004, 00:00

  • PCN25 CASE-MATCHED CONTROLLED STUDY SHOWS MEN PREFER PROSTATE BRACHYTHERAPY TO CONFORMAL RADIATION THERAPY

    May 1, 2004, 00:00

  • PCO4 EPISODES OF RESPIRATORY CARE FOR MANAGED CARE PATIENTS WITH COPD- ASSESSING THE ECONOMIC BURDEN

    May 1, 2004, 00:00

  • PDB1 LOWER INCIDENCE OF MICROVASCULAR EVENTS ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY THAN INSULIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES- A RETROSPECTIVE PROPENSITY SCORE MATCHED COHORT ANALYSIS

    May 1, 2004, 00:00

  • HR4 IMPACT OF MEMBER COST-SHARING LEVELS ON POPULATION-BASED STATIN USE RATES

    May 1, 2004, 00:00

  • PMD9 AGGREGATING COST DATA FROM MULTICENTER CLINICAL TRIALS- AN INCREMENTAL COST-EFFECTIVENESS ELASTICITY APPROACH

    May 1, 2004, 00:00

  • AR2 A COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL TREATMENTS FOR RHEUMATOID ARTHRITI ARTHRITIS

    May 1, 2004, 00:00

  • PMH50 THE ROLE OF ANTIPARKINSONIAN AGENTS IN SELFREPORTED COGNITIVE IMPAIRMENT AND AKATHISIA DURING THE LONG-TERM TREATMENT OF SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PMH25 A COMPARISON OF THE COST-EFFECTIVENESS OF OLANZAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN SELECTED NON-OECD COUNTRIES

    May 1, 2004, 00:00

  • RI2 THE EXCESS COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM A MANAGED-CARE PERSPECTIVE

    May 1, 2004, 00:00

  • PIN23 CLINICAL AND ECONOMIC IMPACT OF HERD IMMUNITY ASSOCIATED WITH HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA

    May 1, 2004, 00:00

  • CE2 PANEL ANALYSIS OF CENSORED MEDICAL COST DATA

    May 1, 2004, 00:00

  • CE4 AN ACTUARIAL APPROACH TO ESTIMATING THE STREAM OF COSTS ASSOCIATED WITH BREAST AND COLORECTAL CANCER

    May 1, 2004, 00:00

  • PCV18 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN

    May 1, 2004, 00:00

  • PMH55 CHILD HEALTH ILLNESS PROFILE AS A QUALITY OF LIFE MEASURE OF CHILDREN WITH ATTENTIONDEFICIT/HYPERACTIVITY DISORDER

    May 1, 2004, 00:00

  • PNL21 INSOMNIA IN A NATIONAL AMBULATORY CARE SETTING 2001

    May 1, 2004, 00:00

  • DB4 DRIVERS OF TREATMENT PREFERENCE AMONG INDIVIDUALS WITH TYPE-2 DIABETES

    May 1, 2004, 00:00

  • HM2 MODELS IDENTIFYING VARIABLES INFLUENCING PHYSICIAN ADOPTION OF NEWLY LAUNCHED PHARMACEUTICALS IN THE UNITED STATES

    May 1, 2004, 00:00

  • PIN21 COMPARISON OF 30-DAY DIRECT MEDICAL COSTS OF AZITHROMYCIN AND LEVOFLOXACIN FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2004, 00:00

  • PHP12 FACTORS AFFECTING CONSUMER VIEWS REGARDING GENERIC DRUG SUBSTITUTION PRACTICES- AN EFFECTIVE TOOL TO MANAGE HEALTH CARE COST

    May 1, 2004, 00:00

  • PCV36 THE IMPACT OF ACEI RELATED COUGH-A SURVEY OF AUSTRALIAN PATIENTS

    May 1, 2004, 00:00

  • PMH15 FACTORS ASSOCIATED WITH SECOND-GENERATION ANITPSYCHOTICS IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH BIPOLAR DISORDERS

    May 1, 2004, 00:00

  • PNL23 PROBABILISTIC SENSITIVITY ANALYSIS OF A COSTEFFECTIVENESS MODEL FOR TRIPTANS (5-HT AGONISTS)

    May 1, 2004, 00:00

  • PMD24 EXPECTED VALUE OF SYMMETRY OF INFORMATION-A FRAMEWORK FOR ASSESSING THE POTENTIAL VALUE OF INDIVIDUALIZING CARE BASED ON PATIENT PREFERENCES

    May 1, 2004, 00:00

  • POS3 HEALTH CARE UTILIZATION AND EXPENDITURES- A STUDY OF SEVERE OSTEOPOROSIS

    May 1, 2004, 00:00

  • SC4 ECONOMIC EVALUATION OF SCREENING FOR THE A-ADDUCIN GENE VARIANT IN HYPERTENSIVE PATIENTS

    May 1, 2004, 00:00

  • MH3 COST-EFFECTIVENESS OF METHYLPHENIDATE OROS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- AN EVALUATION FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

    May 1, 2004, 00:00

  • SC3 FACTORS IMPACTING MAMMOGRAPHY SCREENING IN RURAL AND URBAN AREAS

    May 1, 2004, 00:00

  • PDB20 COST-EFFECTIVENESS OF DULOXETINE VERSUS ROUTINE TREATMENT FOR PAINFUL DIABETIC NEUROPATHY IN A RANDOMIZED TRIAL FROM A SOCIETAL PROSPECTIVE

    May 1, 2004, 00:00

  • PGI6 ECONOMIC BURDEN OF GERD AND PUD IN AN EMPLOYED POPULATION

    May 1, 2004, 00:00

  • PAR4 COST-EFFECTIVENESS OF TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS AS FIRST-LINE AGENTS IN RHEUMATOID ARTHRITIS

    May 1, 2004, 00:00

  • PMH4 ATYPICAL ANTIPSYCHOTIC TREATMENT ADHERENCE AND PERSISTENCE IN A STATE MEDICAID PROGRAM

    May 1, 2004, 00:00

  • PE3 COMORBIDITY INFLUENCE INDEX

    May 1, 2004, 00:00

  • PDB14 PROPENSITY SCORE METHODS FOR REDUCING BIAS IN THE COMPARISON OF COSTS AND UTILIZATION BETWEEN INSULIN LISPRO AND REGULAR INSULIN

    May 1, 2004, 00:00

  • PIN16 COST-EFFECTIVENESS OF FOUR ANTIMICROBIAL REGIMENS IN PATIENTS ADMITTED TO THE MEDICAL FLOOR WITH CLASS IV OR V COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2004, 00:00

  • PAR17 CHARACTERIZATION OF THE TREATMENT OF RHEUMATOID ARTHRITIS FOR PATIENTS PRESCRIBED TUMOR NECROSIS FACTOR-ALPHA INHIBITORS

    May 1, 2004, 00:00

  • PCV44 BMI, SELF-REPORTED COMORBIDITIES, AGE, AND GENDER DO NOT EXPLAIN COUNTRY-SPECIFIC DIFFERENCES IN OBESITYRELATED QUALITY OF LIFE

    May 1, 2004, 00:00

  • PDB23 IS PSYCHOLOGICAL GENERAL WELL-BEING AN IMPORTANT PATIENT-REPORTED OUTCOME FOR THE EVALUATION OF DIABETES DRUG THERAPY?

    May 1, 2004, 00:00

  • PIN20 BURDEN OF ILLNESS OF BACTERIAL CELLULITIS AND ERYSIPELAS OF THE LEG IN THE NETHERLANDS

    May 1, 2004, 00:00

  • PAR8 THE RELATIONSHIP BETWEEN GASTROINTESTINAL SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE IN KOREAN PATIENTS WITH RHEUMATIC DISEASES

    May 1, 2004, 00:00

  • AR3 REVALIDATION OF THE ORIGINAL CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) INSTRUMENT

    May 1, 2004, 00:00

  • PAR7 ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG OSTEOARTHRITIC PATIENTS

    May 1, 2004, 00:00

  • PPN7 TRENDS IN MEDICAL USE AND ABUSE OF SUSTAINEDRELEASE OPIOID ANALGESICS- A REVISIT

    May 1, 2004, 00:00

  • WORK LOSS AND ACTIVITY IMPAIRMENT DUE TO INFLAMMATORY BOWEL DISEASE

    May 1, 2004, 00:00

  • PCV41 MEDICATION POSSESSION RATIOS FOR PATIENTS WITH CALCIUM CHANNEL BLOCKERS AND/OR STATINS

    May 1, 2004, 00:00

  • HR3 COMPARISON OF REIMBURSEMENT SYSTEMS OF VARIOUS COUNTRIES IN CENTRAL AND EASTERN EUROPE, AFRICA, AND MIDDLE EAST

    May 1, 2004, 00:00

  • PBR1 THE ECONOMIC BURDEN OF ANEMIA IN AN INSURED POPULATION

    May 1, 2004, 00:00

  • PCV23 HEALTH CARE AND DRUG UTILIZATION PATTERNS IN PATIENTS RECEIVING LONG TERM THIENOPYRIDINE THERAPY

    May 1, 2004, 00:00

  • PUK11 PATIENT PERSISTENCY WITH MEDICATIONS FOR OVERACTIVE BLADDER

    May 1, 2004, 00:00

  • PCV60 DISORDERS OF LIPOID METABOLISM- LIKELIHOOD OF PRESCRIPTION THERAPY

    May 1, 2004, 00:00

  • CV2 CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS COMPARED TO OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS- AN OBSERVATIONAL STUDY OF A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PUK2 A COST COMPARISON ANALYSIS OF TWO CLINICALLY UROSELECTIVE ALPHA BLOCKERS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    May 1, 2004, 00:00

  • PCN17 THE HEALTH CARE COST OF SMOKING IN CANADA

    May 1, 2004, 00:00

  • PMD1 COMPARISON OF GENERALIZED LINEAR MODELS AND ORDINARY LEAST-SQUARES REGRESSION FOR COST ESTIMATION

    May 1, 2004, 00:00

  • DB1 THE IMPACT OF USING EITHER THE FRAMINGHAM OR THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY RISK FORMULAE IN DIABETES HEALTH ECONOMICS MODELING

    May 1, 2004, 00:00

  • PIN13 AN ECONOMIC AND CLINICAL ASSESSMENT OF FIRST-LINE MONOTHERAPY IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA WITHIN MANAGED CARE

    May 1, 2004, 00:00

  • PDB21 THE IMPACT OF COMMON DIABETIC COMPLICATIONS ON QUALITY OF LIFE

    May 1, 2004, 00:00

  • PHP5 EVALUATING THE COSTS OF DISEASES IMPUTABLE TO STRESS AT WORK

    May 1, 2004, 00:00
  • «
  • 171 (current)
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • »